Login to Your Account

FDA Not Convinced Columbia Lab's Gel has What it Takes

By Mari Serebrov
Washington Editor

Thursday, January 19, 2012
Columbia Laboratories Inc.'s attempt to find a niche for its Prochieve progesterone gel to reduce the risk of preterm birth may have raised more questions than answers, at least as far as the FDA is concerned.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription